
New Alzheimer’s treatments are giving patients and their families some hope, offering a way to slow the disease’s progression. But not everyone has the same opportunity to benefit from these medications.
A new study suggests that Black and Hispanic adults are significantly less likely to receive them than white adults.
Researchers at Michigan Medicine found that Black adults had 86 percent lower odds of receiving anti-amyloid medications than non-Hispanic white adults. Hispanic adults also faced a significant gap, with 79 percent lower odds of receiving treatment.
The findings, published in Neurology, highlight another troubling example of racial disparities in healthcare, this time involving access to newer Alzheimer’s treatments.
For the study, researchers analyzed health records from more than 1 million adults diagnosed with mild cognitive impairment or dementia. They identified 2,427 patients who received anti-amyloid medications and compared them with patients who did not.
Anti-amyloid medications work by targeting amyloid plaques, which are abnormal protein deposits that build up in the brains of people with Alzheimer’s disease. While they don’t cure the disease or reverse existing damage, they can slow cognitive decline in some people early on.
But accessing these treatments isn’t always easy. Researchers found that race, ethnicity, underlying health conditions, and socioeconomic circumstances all played a role in who received medication. People facing greater social and economic disadvantages were nearly half as likely to receive these newer therapies.
RELATED: Alzheimer’s Disease Clinical Trials: What You Need to Know
The treatment gap may actually begin long before a medication reaches the pharmacy. Black Americans are also underrepresented in clinical trials, which can affect how much researchers know about whether new Alzheimer’s treatments work equally well across different populations.
A 2026 study examined 71 Phase 3 Alzheimer’s drug trials conducted in the U.S. between 1997 and 2023. Researchers found that nearly half didn’t report participants’ race or ethnicity. Among the trials that did, white participants made up a median of 91.3 percent of enrollment.
Clinical trials help researchers determine how well treatments work and what side effects patients might experience. When Black adults aren’t adequately represented, researchers have fewer opportunities to evaluate treatment safety and effectiveness across different populations.
The study’s researchers called for more inclusive recruitment efforts, including transportation assistance, language services, financial compensation, and culturally appropriate outreach.

Alzheimer’s affects more than the person diagnosed. Families often take on significant caregiving responsibilities, making access to treatments that could slow disease progression especially important.
The study’s findings reinforce the importance of early evaluation. Families who notice changes in a loved one’s memory, thinking, or behavior should talk with a healthcare provider rather than dismissing them as a normal part of aging.
Patients diagnosed with early Alzheimer’s can also ask their neurologist whether anti-amyloid medications are appropriate for them. Not everyone qualifies, and these drugs require careful screening and monitoring, but knowing what options are available is an important first step.
RELATED: Clinical Trial Finds Web App Manages Aggression and Agitation in Dementia Patients
As Alzheimer’s treatments continue to advance, healthcare providers and researchers must do more to make sure those advances reach everyone. After all, a treatment can’t make a difference if patients never get the chance to receive it.


By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.